Stock APPH APONTIS PHARMA AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Apontis Pharma AG Deutsche Boerse AG

Equities

APPH

DE000A3CMGM5

Market Closed - Deutsche Boerse AG
Other stock markets
 03:41:18 2024-04-26 pm EDT 		5-day change 1st Jan Change
7.98 EUR 0.00% Intraday chart for Apontis Pharma AG +3.91% +70.51%
Apr. 05 Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications MT
Mar. 28 Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's profit outlook over the next few years is a strong asset.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 69 times its estimated earnings per share for the ongoing year.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
APONTIS PHARMA AG Stock Apontis Pharma AG
+70.51% 73.63M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. APPH Stock
  4. APPH Stock
  5. Ratings Apontis Pharma AG